title: A lentiviral vector-based therapeutic vaccine encoding Ag85B-Rv3425 potently increases resistance to acute tuberculosis infection in mice.
abstract: Few treatment options for multidrug-resistant tuberculosis (TB) and extensively drug-resistant TB call attention to the development of novel therapeutic approaches for TB. Therapeutic vaccines are promising candidates because they can induce antigen-specific cellular immune responses, which play an important role in the elimination of Mycobacterium tuberculosis (MTB). In this study, a novel lentiviral vector therapeutic vaccine for delivering MTB-specific fusion protein Ag85B-Rv3425 was constructed. Results showed that one single-injection of this recombinant lentivirus vaccine could trigger antigen-specific Th1-type immune responses in mice. More importantly, mice with acute infection benefited a lot from a single-dose administration of this vaccine by markedly reduced MTB burdens in lungs and spleens as well as attenuated lesions in lungs compared with untreated mice. These results displayed good prospects of this novel vaccine for the immunotherapy of TB.
authors.affiliation: Unit of Anti-Tuberculosis Immunity, Key Laboratory of Molecular Virology and Immunology, Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.
authors.forename: Enzhuo
authors.initials: E
authors.lastname: Yang
authors.affiliation: Department of Medical Microbiology and Parasitology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
authors.forename: Feifei
authors.initials: F
authors.lastname: Wang
authors.affiliation: State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Xu
authors.affiliation: State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200433, China.
authors.forename: Honghai
authors.initials: H
authors.lastname: Wang
authors.affiliation: Department of Neonatology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai 200040, China hbshen@ips.ac.cn huyongcn@163.com.
authors.forename: Yong
authors.initials: Y
authors.lastname: Hu
authors.affiliation: Unit of Anti-Tuberculosis Immunity, Key Laboratory of Molecular Virology and Immunology, Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China hbshen@ips.ac.cn huyongcn@163.com.
authors.forename: Hongbo
authors.initials: H
authors.lastname: Shen
authors.affiliation: Unit of Anti-Tuberculosis Immunity, Key Laboratory of Molecular Virology and Immunology, Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China.
authors.forename: Zheng W
authors.initials: ZW
authors.lastname: Chen
mesh_terms: D000208:Acute Disease; D000217:Acyltransferases / Q000276:immunology*; D056704:Adaptive Immunity; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology*; D001426:Bacterial Proteins / Q000276:immunology*; D005822:Genetic Vectors; D016233:Immunotherapy, Active; D016086:Lentivirus; D051379:Mice; D014376:Tuberculosis / Q000276:immunology / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000942:Antigens, Bacterial; D001426:Bacterial Proteins; C000592808:Rv3425 protein, Mycobacterium tuberculosis; D032581:Tuberculosis Vaccines; D000217:Acyltransferases; C121433:antigen 85B, Mycobacterium tuberculosis
keywords: lentiviral vector; therapeutic vaccine; tuberculosis